Organisation paid for research Program year 2025 Source: CMS Open Payments

Cornell University

Neither a doctor nor a teaching hospital

Research payments

$485,483

70 payments

Through program year 2025, Cornell University is reported as receiving $485,483 in research payments, across 70 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$28,578	14
2024	Research	$119,526	19
2023	Research	$130	1
2022	Research	$26,397	8
2021	Research	$86,920	3
2020	Research	$90,946	16
2019	Research	$132,986	9

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $91,799 2 payments
AstraZeneca Pharmaceuticals LP $65,488 1 payment
PolyNovo North America LLC $60,358 24 payments
Ge Healthcare $51,040 1 payment
Baudax Bio Inc. $50,100 10 payments
Janssen Research & Development, LLC $49,629 5 payments
Celgene Corporation $43,982 7 payments
Urogen Pharma, Inc. $31,416 10 payments
Spark Therapeutics, Inc. $24,500 1 payment
Menarini Silicon Biosystems, Inc. $11,342 4 payments

Studies the money was for Research payments · program years 2019–2025

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men living with HIV $69,081 1 payment
A Multicenter Phase 2 Study of Acalabrutinb, Lenalidomide, Rituximab with Real Time MRD Monitoring in Patients with Previous Untreated MCL $65,488 1 payment
Cp-003 $60,358 24 payments
Advanced Image Guidance in Interventional Radiology $51,040 1 payment
Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma $26,790 2 payments
Dose-Finding Study of Spk-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With Fviii Inhibitors $24,500 1 payment
Phase 3 Study Comparing Daratumumab Bortezomib and Dexamethasone DVd vs Bortezomib and Dexamethasone Vd in Subjects With Relapsed or Refractory Multiple Myeloma $22,839 3 payments
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men living with HIV $22,718 1 payment
PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) $21,897 2 payments
Urogen Pharma Bl007 $20,500 6 payments

What the money was spent on Research payments · program years 2019–2025

Professional salary support $50,100 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.